



For Immediate Release

VICTORY PHARMA ANNOUNCES INVESTIGATIONAL NEW DRUG FOR NOVEL PAIN PRODUCT APPROVED BY THE FOOD AND DRUG ADMINISTRATION

SAN DIEGO, CA (March 29, 2006) – Victory Pharma, Inc. announced today the U.S. Food and Drug Administration (FDA) completed its review of the Company’s Investigational New Drug (IND) application to evaluate MGX-001 for the treatment of pain and a commonly associated side effect of opioid therapy, sedation. The Company plans to conduct a series of clinical studies focused toward MGX-001 regulatory approval. A phase II proof of concept and dose ranging study is planned to initiate in second quarter of 2006. Victory will conduct the study at multiple clinical sites across the United States in conjunction with a leading clinical research organization.

“The IND opening is a significant event in the strategic development of Victory Pharma,” said Dave Gonyer, Vice President of Commercial Development for Victory. “Victory is intent on rapidly creating products based upon our patent estate that provides relief to patients with pain and increases their quality of life. This event also signifies continued growth and capabilities for Victory as a product development organization.”

The field of pain management has experienced significant growth in the recent years. Based on data provided by NDC Health, an independent pharmaceutical market research firm, sales of prescription pharmaceutical products in the U.S. used to treat pain conditions and diseases totaled \$19 billion in 2004 and increased at a compound annual growth rate of 15% from 2000 to 2004. We believe that many factors are continuing to drive growth in the pain management market, including new technologies, an unsatisfied marketplace with increased patient demand for pain relief and an aging population.

About MGX-001

MGX-001, intends to be the first product clinically shown to reduce the sedative effects caused by opioid therapy which can limit pain relief, therapy options and quality of life. According to DataMonitor in 2004, “the greatest unmet needs in nociceptive pain are improved efficacy and fewer side effects”. MGX-001 is the first in a series of products we plan to develop from our intellectual property estate. MGX-001 is scheduled to launch in 2009 with MGX-002 to follow in 2010 and potential for additional products to follow in 2011 and beyond. Combined peak annual revenues for both MGX-001 and MGX-002 are forecast to exceed several hundred million dollars US.

About Victory Pharma, Inc.

Victory Pharma, Inc. is a privately held, specialty pharmaceutical company headquartered in San Diego, CA focused on acquiring, developing and marketing products to treat pain and related products. Victory is currently developing several proprietary products for the treatment of chronic severe pain and commonly associated opiate-induced side effects. Further information regarding Victory is available at www.victorypharma.com.

###

Victory Pharma Contact:
Matt Heck
President
Victory Pharma, Inc.
(858) 720-4511